Translational research in pancreatic cancer

Journal of the Pancreas

Volumn 11, Issue 2, 2010, Pages 124-127

  Strimpakos, Alexios S ^a   Syrigos, Konstantinos N ^a,b   Saif, Muhammad W ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b YALE CANCER CENTER   (United States)

Author keywords

Biological markers; Biological therapy; Gemcitabine; Pancreatic neoplasms; Pharmacogenetics

Indexed keywords

BIOLOGICAL MARKER; CAVEOLIN 1; CRT 0066101; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DNA POLYMERASE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEOSIDE TRANSPORTER; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE D; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESEARCH; CANCER SURVIVAL; CARCINOGENESIS; CODON; CONFERENCE PAPER; DNA POLYMORPHISM; DNA REPAIR; DNA SYNTHESIS; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HUMAN; IMMUNOHISTOCHEMISTRY; KRAS GENE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATICODUODENECTOMY; PHARMACOGENOMICS; PREDICTOR VARIABLE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; ANIMALS; CONGRESSES AS TOPIC; GASTROINTESTINAL NEOPLASMS; GENETICS, POPULATION; HUMANS; MUTATION; PANCREATIC NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; TRANSLATIONAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 77749285630     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics, 2008. CA Cancer J Clin 2008; 58:71-96. [PMID 18287387]
2. Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 2008; 27:495-522. [PMID 18427734]
3. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25:32-42. [PMID 17194903]
4. Kang SP, Saif MW. Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP. J Pancreas (Online) 2008; 9:251-66. [PMID 18469437]
5. Schultz NA, Roslind A, Johansen JS, Høgdall E, Pedersen LN, Christensen JI, et al. KRAS mutations in a population of patients operated for pancreatic adenocarcinoma. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 169.
6. Tan A, Liu X, Rybicki LA, Jiang J, Wang Y, Palma JF, et al. Significance of hENT-1 and RRM1 expression in resected pancreatic cancer. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 166.
7. McWilliams RR, Bamlet WR, Fernandez-Zapico M, Sicotte H, Kim GP, Burch PA, et al. Association of sonic hedgehog variant with survival in pancreatic cancer. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 126.
8. Williams TM, Thomas D, Griffith KA, Rehemtulla A, Zalupski M, Ben-Josef E. Caveolin-1: A potential biomarker of poor prognosis in pancreatic cancer. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 140.
9. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005; 288:C494-C506. [PMID 15692148]
10. Guha S, Harikumar KB, Kunnumakkara AB, Jamieson S, Krishnan S, Aggarwal BB, Ireson CR. Protein kinase D: a novel therapeutic target in pancreatic cancer. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 159.
11. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 2008; 299:1335-44. [PMID 18349094]